NCT00516282终止1 期
A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- MTD of CLORETAZINE
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temozolomide may also stop the growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of VNP40101M when given together with temozolomide and to see how well it works in treating patients with progressive or relapsed malignant glioma.
详细描述
OBJECTIVES:
- To determine the maximum tolerated dose (MTD) of VNP40101M when administered with temozolomide in patients with progressive or relapsed (first relapse) malignant glioma. (Phase I)
- To record the toxicities of VNP40101M when administered with temozolomide. (Phase I and II)
- To measure the level of AGT expression in peripheral blood monocytes before treatment with temozolomide and just prior to the administration of VNP40101M. (Phase I and II)
- To determine MGMT methylation status as well as other methylation patterns in blood and tissue from patients treated with this regimen and correlate with outcome. (Phase I and II)
- To determine the 6- and 12-month progression-free survival rates of patients treated with this regimen. (Phase II)
- To determine overall survival of patients treated with this regimen. (Phase II)
- To determine the complete and partial response rates in patients treated with this regimen. (Phase II)
- To determine CSF penetration of VNP40101M once the MTD is reached from phase I and correlate with serum/plasma pharmacokinetics. (Phase II)
OUTLINE:
- Phase I: Patients receive oral temozolomide on days 1-7 and VNP40101M IV over 15-30 minutes 2 hours after the last dose of temozolomide on day 7. Treatment repeats every 7 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of VNP40101M until the maximum tolerated dose (MTD) is determined The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Inclusion criteria:
- •Histologically proven malignant glioma including any of the following:
- •Glioblastoma multiforme
- •Gliosarcoma
- •Anaplastic astrocytoma
- •Anaplastic oligodendroglioma
- •Anaplastic mixed oligoastrocytoma
- •Malignant astrocytoma not otherwise specified
- •Unequivocal evidence of tumor recurrence or progression by MRI or CT scan with contrast
- •No more than one relapse
- •Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:
- •More than 2 weeks from surgery and have recovered from the effects of surgery
- •Evaluable or measurable disease following resection of recurrent tumor is not mandated for eligibility into the study if a treatment failure can be evaluated
- •Enhanced CT scan/ MRI should be done no later than 96 hours in the immediate post-operative period or 4-6 weeks post-operatively
- •If the 96-hour scan is more than 2 weeks from registration, the scan needs to be repeated
- •A baseline scan should be performed within 14 days prior to registration and on a steroid dosage that has been stable for 5 or more days otherwise a new baseline MRI/CT is required
- •The same type of scan (i.e., MRI or CT scan) must be used throughout the period of protocol treatment for tumor measurement
- •Must have failed prior external-beam radiotherapy
- •Must have failed one prior systemic treatment with chemotherapy or biologic agents
- •PATIENT CHARACTERISTICS:
- •Inclusion criteria:
- •Karnofsky performance status 60-100%
- •Life expectancy > 12 weeks
- •WBC > 3,000/mm³
- •ANC > 1,500/mm³
- •Platelet count > 100,000/mm³
- •Hemoglobin > 10 mg/dL
- •AST and ALT < 4 times upper limit of normal (ULN)
- •Bilirubin < 2 times ULN
- •Creatinine < 1.5 times ULN
- •Fertile patients must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device)
- •Negative pregnancy test
- •Not pregnant or nursing
排除标准
- •Active uncontrolled bleeding
- •Active infection of any kind
- •Unwilling or unable to follow protocol requirements or to give informed consent
- •Active heart disease including any of the following:
- •Myocardial infarction within the past 3 months
- •Uncontrolled arrhythmias
- •Uncontrolled coronary artery disease
- •Uncontrolled congestive heart failure
- •Known HIV-positive patients (HIV testing is not required)
- •History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for that disease for a minimum of 3 years
- •PRIOR CONCURRENT THERAPY:
- •Inclusion criteria:
- •See Disease Characteristics
- •Recovered from prior therapy
- •At least 2 weeks since prior vincristine
- •More than 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)
- •More than 4 weeks since prior radiotherapy
- •More than 4 weeks since prior experimental biologic agents (e.g., EGFR inhibitors, etc)
- •More than 3 weeks since prior procarbazine administration
- •More than 2 weeks since prior non-cytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin)
- •Radiosensitizer does not count
- •At least 2 weeks since prior and no concurrent enzyme inducing anticonvulsants
- •If patient is on an enzyme inducing anticonvulsant, they may be converted to a non-enzyme inducing anticonvulsant
- •Exclusion criteria:
- •Any other concurrent standard or investigational treatment for cancer, or any other investigational agent for any indication
- •Concurrent disulfiram
结局指标
主要结局
MTD of CLORETAZINE
时间窗: At the end of phase one
To determine the MTD of CLORETAZINE when administered with Temodar® in patients with malignant gliomas in first or second relapse
Progression-free survival rate
时间窗: End of Phase II
To determine the 6 and 12 month progression-free survival rate.
次要结局
- Toxicities of CLORETAZINE when administered with Temodar®.(Adverse events are monitored at screening/baseline;day one; termination visit; followup until death.)
- Response rate to CLORETAZINE after Temodar® in patients with malignant gliomas in first or second relapse(Day one of every cycle)
- Record the toxicities of CLORETAZINE when administered after Temodar(Continuously after the first dose;within thirty days of each administration of investigational agent)
- MGMT Methylation Status(Baseline and day seven of every cycle)
- Determine overall survival(All patients will be followed until death)
- Measure the level of AGT expression(Day seven of every cycle)
- CSF penetration of CLORETAZINE(Day seven of cycle one of Phase 2 only)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory LeukemiasLeukemiaNCT00098436Vion Pharmaceuticals25
Unknown
2 期
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid LeukemiaLeukemiaNCT00354276Vion Pharmaceuticals85
已完成
3 期
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaLeukemiaNCT00112554Vion Pharmaceuticals420
已完成
2 期
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung CancerLung CancerNCT00282022Vion Pharmaceuticals87
已完成
1 期
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative DisordersLymphomaLeukemiaNCT00304005Vion Pharmaceuticals35